Quetiapine: novel uses in the treatment of depressive and anxiety disorders

Bibliography

• Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005;79:145-55
   PubMed Web of Science ®Google Scholar
• Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 2005;20:183-98
   PubMed Web of Science ®Google Scholar
• Shen WW. A history of antipsychotic drug development. Compr Psychiatry 1999;40:407-14
   PubMed Web of Science ®Google Scholar
• Cohen LJ. Evaluation of new drugs: risperidone. Pharmacotherapy 1994;14:253-65
   PubMed Web of Science ®Google Scholar
• Riedel M, Schennach-Wolff R, Musil R, Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum Psychopharmacol 2010;25:116-25
   PubMed Web of Science ®Google Scholar
• Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 2007;89:211-24
   PubMed Web of Science ®Google Scholar
• Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 2004;65:975-81
   PubMed Web of Science ®Google Scholar
• Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 2006;67:1327-40
   PubMed Web of Science ®Google Scholar
• Shea S, Turgay A, Carroll A, Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:634-41
   PubMed Web of Science ®Google Scholar
• Billups NF, editor. American drug index 2007. 51st edition. Lippincott Williams & Wilkins, New York; 2006
   Google Scholar
• Canadian Pharmacists Association (Ed.). Compendium of pharmaceuticals and specialties. The Canadian drug reference for professionals. Canadian Pharmacists Association, Toronto; 2009
   Google Scholar
• Sweetman S, editor. The complete drug reference. 35th edition. Pharmaceutical Press, London; 2007
   Google Scholar
• Thase ME, Macfadden W, Weisler RH, Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II Study). J Clin Psychopharmacol 2006;26:600-9
   PubMed Web of Science ®Google Scholar
• Denys D, De Geus F, Van Megan HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004;65:1040-8
   PubMed Web of Science ®Google Scholar
• Hamner MB, Deitsch SE, Brodrick PS, Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 2003;23:15-20
   PubMed Web of Science ®Google Scholar
• Devane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine. An atypical antipsychotic. Clin Pharmacokinet 2001;40:509-22
   PubMed Web of Science ®Google Scholar
• Goldstein JM. The new generation of antipsychotic drugs: how atypical are they? Int J Neuropsychopharmacol 2000;3:339-49
   PubMed Web of Science ®Google Scholar
• Jensen NH, Rodriguiz RM, Caron MG, N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008;33:2303-12
   PubMed Web of Science ®Google Scholar
• Millan MJ, Brocco M, Rivet J-M, S18327, a novel, potential antipsychotic displaying marked antagonist properties at a1 and a2 adrenergic receptors: II Functional profile and a multiparametric comparison to haloperidol, clozapine and 11 other antipsychotic agents. J Pharmacol ExpTher 2000;292:54-66
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptro occupancy. Arch Gen Psychiatry 2000;57:553-9
   PubMed Web of Science ®Google Scholar
• Kuroki T, Nago N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 2008;172:199-212
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Soczynska JK, Woldeyohannes HO, A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007;8:1211-19
   PubMed Web of Science ®Google Scholar
• Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(2):199-204
   PubMed Web of Science ®Google Scholar
• Meulien D, Huizar K, Brecher M. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies. Hum Psychopharmacol 2010;25(2):103-15
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci 2000;68:29-39
   PubMed Web of Science ®Google Scholar
• Cohr S, Roher C, Jordan W, Atypical antipsychotics olanzapine and quetiapine but not haloperidol reduce ACTH and cortisol as seen in health controls. Psychopharmacol 2006;185:11-18
   Web of Science ®Google Scholar
• Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003;70:83-244
   PubMed Web of Science ®Google Scholar
• Tobin ML. Psychopharmacology update: why choose quetiapine for bipolar illness? Issues Ment Health Nurs 2007;28:437-9
   PubMedGoogle Scholar
• Perris C. Bipolar-unipolar distinction. In: Paykel ES, editor, Handbook of affective disorders. The Guilford Press, New York; 1992. p. 57-75
   Google Scholar
• Weisler RH, Calabrese JR, Thase ME, Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008;69:769-82
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). Revised 4th edition. American Psychiatric Association, Washington, DC; 2000
   Google Scholar
• Patten SB, Kennedy SH, Lam RW, ; Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. J Affect Disord 2009;117(Suppl 1):S5-14
   PubMed Web of Science ®Google Scholar
• World Health Organization. The global burden of disease – 2004 update, 2008. Available from: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html [Last accessed 21 February 2010]
   Google Scholar
• Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370
   PubMed Web of Science ®Google Scholar
• Lam RW, Kennedy SH, Grigoriadis S, ; Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009;117(Suppl 1):S26-43
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Muzina DJ, Adams A, Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother 2009;10:3061-75
   PubMed Web of Science ®Google Scholar
• Baune BT. New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine. Neuropsychiatry Dis Treat 2008;4:1181-91
   PubMedGoogle Scholar
• Weisler R, Joyce M, McGill L, Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009;14:299-313
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Montgomery SA, Feifel D, Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009;70:526-39
   PubMed Web of Science ®Google Scholar
• Datto C, Lam R, Lepola U, Double-blind study of extended release quetiapine fumarate (quetiapine XR) monotherapy for maintenance treatment of major depressive disorder (MDD). Abstract presented at the 161st Annual Meeting of the American Psychiatric Association; Washington, DC; 2008
   Google Scholar
• Bauer M, Pretorius HW, Constant EL, Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009;70:540-9
   PubMed Web of Science ®Google Scholar
• El-Khalili N, Joyce M, Atkinson S, Adjunctive extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder and inadequate antidepressant response. Abstract presented at the 161st Annual Meeting of the American Psychiatric Association; Washington, DC, 2008
   Google Scholar
• DelBello MP, Adler CM, Whitsel RM, A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry 2007;68:789-95
   PubMed Web of Science ®Google Scholar
• Carta MG, Zairo F, Mellino G, Hardoy MC. Add-on quetiapine in the treatment of major depressive disorder in elderly patients with cerebrovascular damage. Clin Pract Epidemiol Ment Health 2007;3:28
   PubMedGoogle Scholar
• Wijeratne C, Sachdev P. Treatment-resistant depression: critique of current approaches. Aust NZ J Psychiatry 2008;42:751-62
   PubMed Web of Science ®Google Scholar
• Rush A, Trivedi M, Wisniewski S, Acute and longerterm outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
   PubMed Web of Science ®Google Scholar
• Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009;70(Suppl 6):16-25
   PubMed Web of Science ®Google Scholar
• Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. BMC Psychiatry 2008;8:73
   PubMed Web of Science ®Google Scholar
• Doree JP, Des Rosiers J, Lew V, Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin 2007;23:333-41
   PubMed Web of Science ®Google Scholar
• Anderson IM, Sarsfield A, Haddad PM. Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study. J Affect Disord 2009;117:116-19
   PubMed Web of Science ®Google Scholar
• Baune BT, Caliskan S, Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol 2007;22:1-9
   PubMed Web of Science ®Google Scholar
• Sagud M, Mihaljevic-Peles A, Muck-Seler D, Quetiapine augmentation in treatment-resistant depression: a naturalistic study. Psychopharmacology (Berl) 2006;187:511-14
   PubMed Web of Science ®Google Scholar
• Devarajan S, Ali J, Dursun SM. Quetiapine plus SSRI in treatment-resistant depression: possible mechanisms. Psychopharmacology (Berl) 2006;185:402-3
   PubMed Web of Science ®Google Scholar
• Good CR. Adjunctive quetiapine targets self-harm behaviours in adolescent females with major depressive disorder. J Child Adolesc Psychopharmacol 2006;16:235-6
   PubMed Web of Science ®Google Scholar
• Pathak S, Johns ES, Kowatch RA. Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. J Child Adolesc Psychopharmcol 2005;15:696-702
   PubMed Web of Science ®Google Scholar
• Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biol Psychiatry 2003;53:680-90
   PubMed Web of Science ®Google Scholar
• Keller J, Schatzberg AF, Maj M. Current issues in the classification of psychotic major depression. Schizophr Bull 2007;33:877-85
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Winer J, Flint AJ, ; Study of Pharmacotherapy of Psychotic Depression (STOP-PD) Collaborative Study Group. Missed diagnosis of psychotic depression at 4 academic medical centers. J Clin Psychiatry 2008;69:1293-6
   PubMed Web of Science ®Google Scholar
• Berger GE, Proffitt TM, McConchie M, Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, toleralibity, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15-25 years. J Clin Psychiatry 2008;69:1702-14
   PubMed Web of Science ®Google Scholar
• Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23:1839-54
   PubMed Web of Science ®Google Scholar
• Wijkstra J, Burger H, van den Broek WW, Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine and venlafaxine plus quetiapine. Acta Psychiatr Scand 2010;121:190-200
   PubMed Web of Science ®Google Scholar
• Konstantinidis A, Hrubos W, Nirnberger G, Quetiapine in combination with citalopram in patients with unipolar psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:242-7
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Rothschild A, Fletcher KE, Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000;61:185-9
   PubMed Web of Science ®Google Scholar
• Shaw JA, Lewis JE, Pascal S, A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 2001;11:415-24
   PubMed Web of Science ®Google Scholar
• Padla D. Quetiapine resolves psychotic depression in an adolescent boy. J Child Adolesc Psychopharmacol 2001;11:207-8
   PubMed Web of Science ®Google Scholar
• Castro-Fornieles J, Parellada M, Soutullo CA, Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. J Child Adolesc Psychopharmacol 2008;18:327-36
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JBW, Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007;146:317-25
   PubMed Web of Science ®Google Scholar
• Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry 2006;51:100-13
   PubMed Web of Science ®Google Scholar
• Deakin JF. The role of serotonin in panic, anxiety and depression. Int Clin Psychopharmacol 1998;13(Suppl 4):S1-5
   PubMed Web of Science ®Google Scholar
• Pollack MH, Otto MW, Roy-Byrne PP, Novel treatment approaches for refractory anxiety disorders. Depress Anxiety 2008;25:467-76
   PubMed Web of Science ®Google Scholar
• Canadian Psychiatric Association. Clinical practice guidelines for the treatment of anxiety disorders. Can J Psychiatry 2006;51(Suppl 2):S1-93
   Google Scholar
• Bandelow B, Chouinard G, Bobes J, Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2009;20:1-16
   Google Scholar
• Khan A, Joyce M, Eggens I, Extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of patients with generalized anxiety. Abstract presented at the Anxiety Disorders Association of America Congress; Savannah, Georgia, USA; 2008
   Google Scholar
• Katzman M, Brawman-Mintzer O, Reyes E, Extended release quetiapine fumarate (quetiapine XR) monotherapy in maintenance treatment of generalized anxiety disorder (GAD): efficacy and tolerability results from a randomized, placebo-controlled trial. Abstract presented at the 63rd Annual Meeting of the Society of Biological Psychiatry; Washington, DC; 2008
   Google Scholar
• Simon NM, Connor KM, LeBeau RT, Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl) 2008;197:675-81
   PubMed Web of Science ®Google Scholar
• Katzman MA, Vermani M, Jacobs L, Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord 2008;22:1480-6
   PubMed Web of Science ®Google Scholar
• Vaishnavi S, Alamy S, Zhang W, Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1464-9
   PubMed Web of Science ®Google Scholar
• Donahue CB, Kushner MG, Thuras PD, Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia. J Anxiety Disord 2009;23:362-8
   PubMed Web of Science ®Google Scholar
• Schutters SI, van Megen HJ, Westenberg HG. Efficacy of quetiapine in generalized social anxiety disorders: results from an open-label study. J Clin Psychiatry 2005;66:540-2
   PubMed Web of Science ®Google Scholar
• Kozaric-Kovacic D, Pivac N. Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. Int J Neuropsychopharmacol 2007;10:253-61
   PubMed Web of Science ®Google Scholar
• Hamner MB, Deitsch SE, Brodrick PS, Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 2003;23:15-20
   PubMed Web of Science ®Google Scholar
• Ahearn EP, Mussey M, Johnson C, Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. Int Clin Psychopharmacol 2006;21:29-33
   PubMed Web of Science ®Google Scholar
• Sattar SP, Ucci B, Grant K, Quetiapine therapy for posttraumatic stress disorder. Ann Pharmacother 2002;36:1875-8
   PubMed Web of Science ®Google Scholar
• Filteau MJ, Leblanc J, Bouchard R-H. Quetiapine reduces flashbacks in chronic posttraumatic stress disorder. Can J Psychiatry 2003;48:282-3
   PubMed Web of Science ®Google Scholar
• Stathis S, Martin G, McKenna JG. A preliminary case series on the use of quetiapine for posttraumatic stress disorder in juveniles within a youth detention center. J Clin Psychopharmacol 2005;25:539-44
   PubMed Web of Science ®Google Scholar
• Bloch MH, Landerso-Weisenberger A, Kelmendi B, A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006;11:622-32
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Stein DJ, Premkumar P, Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol 2006;21:337-43
   PubMed Web of Science ®Google Scholar
• Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 2007;17:79-93
   PubMed Web of Science ®Google Scholar
• Denys D, Fineberg N, Carey PD, Stein DJ. Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry 2007;61:412-14
   PubMed Web of Science ®Google Scholar
• Kordon A, Wahl K, Koch N, Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychopharmacol 2008;28:550-4
   PubMed Web of Science ®Google Scholar
• de Geus F, Denys D, Westenberg HG. Effects of quetiapine on cognitive functioning in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007;22:77-84
   PubMed Web of Science ®Google Scholar
• Matsunaga H, Nagata T, Hayashida K, A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 2009;70:863-8
   PubMed Web of Science ®Google Scholar
• Vulink NC, Denys D, Fluitman SB, Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry 2009;70:1001-8
   PubMed Web of Science ®Google Scholar
• Diniz J, Shavitt R, Pereira C, Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J Psychopharmacol 2010;24:297-307
   PubMed Web of Science ®Google Scholar
• Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open label study. J Clin Psychiatry 2002;63:700-3
   PubMed Web of Science ®Google Scholar
• Misri S, Milis L. Obsessive-compulsive disorder in the postpartum: open-label trial of quetiapine augmentation. J Clin Psychopharmacol 2004;24:624-7
   PubMed Web of Science ®Google Scholar
• Bogan AM, Koran LM, Chuong HW, Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J Clin Psychiatry 2005;66:73-9
   PubMed Web of Science ®Google Scholar
• Sevincok L, Topuz A. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. J Clin Psychopharmacol 2003;23:448-50
   PubMed Web of Science ®Google Scholar
• Mohr N, Vythilingum B, Emsley RA, Stein DJ. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol 2002;17:37-40
   PubMed Web of Science ®Google Scholar
• Francobandiera G. Quetiapine augmentation of sertraline in obsessive-compulsive disorder. J Clin Psychiatry 2002;63:1046-7
   PubMed Web of Science ®Google Scholar
• Dell'Osso B, Mundo E, Altamura AC. Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a six-month follow-up case series. CNS Spectr 2006;11:879-83
   PubMed Web of Science ®Google Scholar
• Matur Z, Ucok A. Quetiapine treatment in a patient with Tourette's syndrome, obsessive-compulsive disorder and drug-induced mania. Isr J Psychiatry Relat Sci 2003;40:150-2
   PubMed Web of Science ®Google Scholar
• Cohen LS. Quetiapine in treatment-resistant obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2003;42:623-4
   PubMed Web of Science ®Google Scholar
• Hollander E. Treatment of obsessive-compulsive spectrum disorders with SSRIs. Br J Psychiatry 1998;173(Suppl 35):7-12
   Google Scholar
• Pauls DL, Alsobrook JP, Goodman WK, A family study of obsessive compulsive disorder. Am J Psychiatry 1995;152:76-84
   PubMed Web of Science ®Google Scholar
• Rasmussen SA. Obsessive-compulsive spectrum disorders. J Clin Psychiatry 1994;55:89-91
   PubMed Web of Science ®Google Scholar
• Ravindran AV, da Silva TL, Ravindran LN, Obsessive-compulsive spectrum disorders: a review of the evidence-based treatments. Can J Psychiatry 2009;54:331-43
   PubMed Web of Science ®Google Scholar
• Herzog D, Greenwood DN, Dorer DJ, Mortality in eating disorders: a descriptive study. Int J Eat Disord 2000;28:20-6
   PubMed Web of Science ®Google Scholar
• Bosanac P, Kurlender S, Norman T, An open-label study of quetiapine in anorexia nervosa. Hum Psychopharmacol 2007;22:223-30
   PubMed Web of Science ®Google Scholar
• Powers P, Bannon Y, Eubanks R, McCormick T. Quetiapine in anorexia nervosa patients: an open label outpatient pilot study. Int J Eat Disord 2007;40:21-6
   PubMed Web of Science ®Google Scholar
• Swedo S, Leonard H, Lenane M, Rettew DC. Trichotillomania: a profile of the disorder from infancy through adulthood. Int Pediatrics 1992;7:144-50
   Google Scholar
• Khouzam HR, Battista MA, Byers PE. An overview of trichotillomania and its response to treatment with quetiapine. Psychiatry 2002;65:261-70
   PubMed Web of Science ®Google Scholar
• Crescente JA Jr, Guzman CS, Tavares H. Quetiapine for the treatment of trichotillomania. Rev Bras Psiquiatr 2008;30:402
   PubMed Web of Science ®Google Scholar
• Zinner SH. Tourette disorder. Pediatr Rev 2000;21:372-83
   PubMedGoogle Scholar
• Scahill L, Tanner C, Dure L. The epidemiology of tics and Tourette syndrome in children and adolescents. Adv Neurol 2001;85:261-71
   PubMedGoogle Scholar
• de Jonge JL, Cath DC, van Balkom AJ. Quetiapine in patients with Tourette's disorder: an open-label, flexible-dose study. J Clin Psychiatry 2007;68:1148-50
   PubMed Web of Science ®Google Scholar
• Mukkades NM, Abali O. Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol 2003;13:295-9
   PubMed Web of Science ®Google Scholar
• Copur M, Arpaci B, Demir T, Narin H. Clinical effectiveness of quetiapine in children and adolescents with Tourette's syndrome: a retrospective case-note survey. Clin Drug Investig 2007;27:123-30
   PubMed Web of Science ®Google Scholar
• Parraga HC, Parraga MI, Woodward RL, Fenning PA. Quetiapine treatment of children with Tourette's syndrome: a report of two cases. J Child Adolesc Psychopharmacol 2001;11:187-91
   PubMed Web of Science ®Google Scholar
• Lepine JP, Wittchen H-U, Essau CA, Lifetime and current comorbidity of anxiety and depressive disorders: results from the international WHO/ADAMHA CIDI field trials. Int J Methods Psychiatr Res 1993;3:67-77
   Web of Science ®Google Scholar
• Hirschfeld RM. The comorbidity of major depression and anxiety disorders: recognition and management in primary care. Prim Care Companion J Clin Psychiatry 2001;3:244-54
   PubMedGoogle Scholar
• Hranov LG. Comorbid anxiety and depression: illumination of a controversy. Int J Psychiatry Clin Prac 2007;11:171-89
   PubMed Web of Science ®Google Scholar
• Ravindran AV, Ravindran LN. Depression and comorbid anxiety: an overview of pharmacological options. Psychiatr Times 2009;26:53
   Google Scholar
• McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007;24:487-94
   PubMed Web of Science ®Google Scholar
• Adson DE, Kushner MG, Eiben KM, Schulz SC. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety 2004;19:121-6
   PubMed Web of Science ®Google Scholar
• Galynker I, Khan A, Grebchenko Y, Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. J Clin Psychiatry 2005;66:544
   PubMed Web of Science ®Google Scholar
• Shelton PS, Barnett FL, Krick SE. Hyperventilation associated with quetiapine. Ann Pharmacother 2000;34:335-7
   PubMed Web of Science ®Google Scholar
• Stamouli S, Lykouras L. Quetiapine-induced obsessive-compulsive symptoms: a series of five cases. J Clin Psychopharmacol 2006;26:396-400
   PubMed Web of Science ®Google Scholar
• Kohen I, Gordon ML, Manu P. Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports. CNS Spectr 2007;12:596-8
   PubMed Web of Science ®Google Scholar
• Patel NC, Kistler JS, James EB, Crismon ML. A restrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy 2004;24:824-30
   PubMed Web of Science ®Google Scholar
• Staller J. The effect of long-term antipsychotic treatment on prolactin. J Child Adolesc Psychopharmacol 2006;16:317-26
   PubMed Web of Science ®Google Scholar
• Stevens JR, Kymissis PI, Baker AJ. Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol 2005;15:893-900
   PubMed Web of Science ®Google Scholar
• Tenyi T, Trixler M, Keresztes Z. Quetiapine and pregnancy. Am J Psychiatry 2002;159:674
   PubMed Web of Science ®Google Scholar
• Taylor TM, O'Toole MS, Ohlsen RI, Safety of quetiapine during pregnancy. Am J Psychiatry 2003;160:588-9
   PubMed Web of Science ®Google Scholar
• Cabuk D, Sayin A, Derinoz O, Biri A. Quetiapine use for the treatment of manic episode during pregnancy. Arch Womens Ment Health 2007;10:235-6
   PubMed Web of Science ®Google Scholar
• Gentile S. Quetiapine-fluvoxamine combination during pregnancy and while breastfeeding. Arch Womens Ment Health 2006;9:158-9
   PubMed Web of Science ®Google Scholar
• Klier CM, Mossaheb N, Saria A, Pharmacokinetics and elimination of quetiapine, venlafaxine, and trazodone during pregnancy and postpartum. J Clin Psychopharmacol 2007;27:720-2
   PubMed Web of Science ®Google Scholar
• McKenna K, Koren G, Tetelbaum M, Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005;66:444-9
   PubMed Web of Science ®Google Scholar
• Newport DJ, Calamaras MR, DeVane CL, Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 2007;164:1214-20
   PubMed Web of Science ®Google Scholar
• Lee A, Giesbrecht E, Dunn E, Ito S. Excretion of quetiapine in breast milk. Am J Psychiatry 2004;161:1715-16
   PubMed Web of Science ®Google Scholar
• Misri S, Corral M, Wardrop AA, Kendrick K. Quetiapine augmentation in lactation: a series of case reports. J Clin Psychopharmacol 2006;26:508-11
   PubMed Web of Science ®Google Scholar
• Philip NS, Carpenter LL, Tyrka AR, Price LH. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. J Psychiatr Pract 2008;14:34-44
   PubMed Web of Science ®Google Scholar
• Gao K, Sheehan DV, Calabrese JR. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother 2009;9:1147-58
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006;75:139-53
   PubMed Web of Science ®Google Scholar
• Meyers BS, Flint AJ, Rothschild AJ, ; STOP-PD Group. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009;66:838-47
   PubMed Web of Science ®Google Scholar
• Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166:980-91
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Thase ME, Fava M, Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry 2008;69:1928-36
   PubMed Web of Science ®Google Scholar
• Ravindran AV, Bradbury C, McKay M, da Silva TL. Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders. Expert Opin Pharmacother 2007;8:1693-710
   PubMed Web of Science ®Google Scholar
• Kaufman J, Charney D. Comorbidity of mood and anxiety disorders. Depress Anxiety 2000;12(Suppl 1):69-76
   PubMed Web of Science ®Google Scholar
• Lee MS, Lee HY, Kang SG, Variables influencing antidepressant medication adherence for treating outpatients with depressive disorders. J Affect Disord 2009. [Epub ahead of print]
   Google Scholar
• Weiden PJ, Schooler NR, Weedon JC, A randomized controlled trial of long-acting risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 2009;70:1397-406
   PubMed Web of Science ®Google Scholar